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Purpose: Extrafine-particle inhaled corticosteroids (ICS) have greater small airway deposition than standard fine-particle ICS. We sought to com-
pare asthma-related outcomes after patients initiated extrafine-particle ciclesonide or fine-particle ICS (fluticasone propionate or non-extrafine be-
clomethasone). Methods: This historical, matched cohort study included patients aged 12-60 years prescribed their first ICS as ciclesonide or fine-
particle ICS. The 2 cohorts were matched 1:1 for key demographic and clinical characteristics over the baseline year. Co-primary endpoints were 
1-year severe exacerbation rates, risk-domain asthma control, and overall asthma control; secondary endpoints included therapy change. Results: 
Each cohort included 1,244 patients (median age 45 years; 65% women). Patients in the ciclesonide cohort were comparable to those in the fine-
particle ICS cohort apart from higher baseline prevalence of hospitalization, gastroesophageal reflux disease, and rhinitis. Median (interquartile 
range) prescribed doses of ciclesonide and fine-particle ICS were 160 (160-160) μg/day and 500 (250-500) μg/day, respectively (P<0.001). During 
the outcome year, patients prescribed ciclesonide experienced lower severe exacerbation rates (adjusted rate ratio [95% CI], 0.69 [0.53-0.89]), and 
higher odds of risk-domain asthma control (adjusted odds ratio [95% CI], 1.62 [1.27-2.06]) and of overall asthma control (2.08 [1.68-2.57]) than those 
prescribed fine-particle ICS. The odds of therapy change were 0.70 (0.59-0.83) with ciclesonide. Conclusions: In this matched cohort analysis, we 
observed that initiation of ICS with ciclesonide was associated with better 1-year asthma outcomes and fewer changes to therapy, despite data 
suggesting more difficult-to-control asthma. The median prescribed dose of ciclesonide was one-third that of fine-particle ICS. 
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INTRODUCTION
Asthma management guidelines recommend anti-inflamma-
tory controller therapy to attenuate chronic airway inflamma-
tion in persistent asthma.1-3 Inhaled corticosteroids (ICSs) are 
available inpressurized metered dose inhalers (pMDI) using a 
hydrofluoroalkane propellant as both fine-particle formulations 
with a particle mass median aerodynamic diameter (MMAD) of 
2-4 µm and as aerosols of extrafine particles with an MMAD-1 
µm.4-6
Ciclesonide is an extrafine-particle ICS (MMAD 1.0 µm) that 
shows both high lung deposition and peripheral lung distribu-
tion in healthy volunteers and patients with asthma.7,8 Results 
of small studies in patients with mild-to-moderate asthma indi-
cate that ciclesonide improves inflammation and patency of 
small airways9 and, compared to fluticasone (MMAD 2.4-2.6 
µm), provides greater improvement in small airway function, 
inflammation, and hyperresponsiveness to small-particle aero-
solized adenosine monophosphate (MMAD 1.04 µm).10,11 As 
small airways dysfunction may be involved in unstable asth-
ma,4,12-14 these findings raise the question whether there are dif-
ferences ineffectiveness between extrafine- and fine-particle 
ICSs.
In clinical trials to date, ciclesonide showed similar efficacy as 
compared with fine-particle ICSs, such as fluticasone and 
budesonide (MMAD ~3 µm) at similar nominal doses for pa-
tients with persistent asthma.10,15,16 However, these trials were 
generally 8-12 weeks in duration and focused on short-term 
improvement of lung function outcomes, thus they were un-
able to assess longer term fluctuations in asthma control and 
events, such as exacerbations. Moreover, smokers and patients 
with unstable asthma, who may both have more prominent 
small airways disease,4,17 were typically excluded, as were pa-
tients with poor inhaler techniques, who might also benefit 
from extrafine-particle ICSs.18 Thus, the question remains 
whether ICS particle size plays a role in long-term effectiveness 
of ICS therapy.
Non-interventional observational studies using high-quality 
databases can capture prescribing and medical record infor-
mation to assess long-term outcomes for patients with asthma 
often excluded from clinical trials but commonly seen by clini-
cians, such as smokers, patients with poor inhaler techniques, 
patients at high risk of exacerbation, and those with comorbidi-
ties.14,17,19,20 Previous database studies in the UK and USA have 
found in matched cohort analyses that the prescription of ex-
trafine-particle beclomethasone was associated with equal, or 
better, asthma-related outcomes over a 1-year period, at signifi-
cantly lower prescribed ICS doses, than standard fine-particle 
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fluticasone.21,22 The aim of the current historical cohort study 
was to compare 1-year asthma-related outcomes between ex-
trafine particle ciclesonide and 2 standard fine-particle ICS, 
fluticasone and non-extrafine beclomethasone, for patients in 
the Netherlands prescribed their first ICS.
MATERIALS AND METHODS
Data source
This was a historical, matched cohort effectiveness study of 
patients registered from September 2005 through December 
2012 in the PHARMO Database Network (PHARMO Institute, 
Utrecht, The Netherlands), which links outpatient pharmacy 
and hospital discharge records for a catchment area represent-
ing 3.6 million residents (additional detail is provided in the 
Online Supplement).23-25 The study was conducted to standards 
suggested for observational research, including an indepen-
dent advisory group, use of an a priori analysis plan, and study 
registration.26-28
Patients and study design
Patients eligible for this study were aged 12-60 years, had ≥1 
full year of baseline and ≥1 full year of outcome data before 
and after their first recorded prescription of ICS (initiation 
date), and had received 2 or more prescriptions for asthma at 
any time in their records in addition to the first ICS prescrip-
tion, including at least 1 more ICS prescription during outcome 
(but no ICS during the baseline year); therefore, all patients in-
cluded received at least 2 ICS prescriptions. We excluded pa-
tients >60 years old, those with any other recorded chronic re-
spiratory disease, and those prescribed long-acting muscarinic 
antagonists or maintenance oral corticosteroid therapy during 
the baseline year.
At the initiation date, patients received a first prescription of 
ICS delivered using a pMDI as the extrafine-particle ICS cicle-
sonide (Alvesco®, Takeda Pharmaceuticals International 
GmbH, Zurich, Switzerland) or a pMDI fine-particle ICS, either 
fluticasone propionate (Flixotide®, GlaxoSmithKline, Brentford, 
Middlesex, UK) or non-extrafine beclomethasone dipropionate 
(Supplementary Fig. 1).
Study endpoints
Co-primary endpoints were assessed during 1 outcome year 
after initiation of ICS therapy and included (1) the rate of severe 
exacerbations, defined as asthma-related hospital admission or 
acute oral corticosteroid prescription (based on the American 
Thoracic Society/European Respiratory Society definition29 ex-
cluding emergency department attendance, not available in 
the database); (2) risk-domain asthma control, defined as the 
absence of severe exacerbations; and (3) overall asthma con-
trol, defined as achieving risk-domain asthma control plus 
mean daily dose of albuterol of ≤200 µg. Secondary endpoints 
included the change in therapy and mean daily dose of short-
acting β2-agonists (SABA) during the outcome period (addi-
tional detail in the Online Supplement).
Statistical analysis
Analyses were carried out using IBM SPSS Statistics version 
22, Microsoft Office EXCEL 2007, and SAS version 9.3. Statistical 
significance was defined as P<0.05. Chi-square or Mann Whit-
ney U-tests (unmatched data) and conditional logistic regres-
sion (matched data) were used to compare treatment cohorts 
at baseline.
Patients in the 2 cohorts were matched using 1:1 exact-match-
ing methods,30 described in the Online Supplement. Matching 
variables were sex, age, baseline risk-domain asthma control, 
prescribed long-acting β2-agonist, SABA daily dose, prescribed 
leukotriene receptor antagonist, prescribed antifungal medica-
tion for oral candidiasis, and year of ICS therapy initiation.
A conditional Poisson regression model was used to compare 
the rates of severe exacerbations and hospitalizations for 
matched patients. Conditional binary logistic regression was 
used to compare the odds of achieving asthma control, being 
prescribed higher doses of SABA, and changing therapy. Rate 
ratios and odds ratios, with 95% confidence intervals, were ad-
justed for appropriate non-collinear confounders.
RESULTS
Patients
There were 4,064 eligible patients identified in the database 
during the study period; 1,382 (34%) were prescribed extrafine-
particle ciclesonide, and 2,682 (66%) fine-particle ICS. Applying 
the matching criteria led to 1,244 patients being selected in 
each treatment cohort (Supplementary Fig. 2).
After matching, baseline asthma control measures, SABA dai-
ly dose, and prior maintenance asthma therapy were compara-
ble between the cohorts (Table 1). Asthma-related hospital ad-
missions during the baseline year, while generally infrequent, 
were significantly more prevalent in the ciclesonide cohort (Ta-
ble 1); significantly more patients who received ciclesonide had 
evidence of rhinitis (43% vs 38%; P=0.004) and were prescribed 
proton pump inhibitors (41% vs 34%; P<0.001) than those who 
received fine-particle ICS.
At the initiation date, ciclesonide was prescribed at signifi-
cantly lower doses than fine-particle ICS (median [interquartile 
range] 160 [160-160] vs 500 [250-500] µg; P<0.001). The distri-
bution of doses at initiation (Fig. 1) shows clear separation be-
tween ciclesonide (mostly 160 µg/day) and fine-particle ICS 
(mostly ≥500 µg/day, especially for fluticasone) (Supplemen-
tary Table 1).
Co-primary endpoints
During the outcome year, patients prescribed ciclesonide had 
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significantly lower severe asthma exacerbation rates (adjusted 
rate ratio [95% CI], 0.69 [0.53-0.89]) and significantly greater 
odds of achieving risk-domain asthma control (defined as ab-
sence of asthma-related hospital admissions and of prescrip-
tions of acute oral corticosteroids) and overall asthma control 
(defined as risk-domain asthma control plus average daily dose 
of ≤200 µg albuterol) than those receiving fine-particle ICS ther-
apy, after adjusting for baseline confounders (Table 2 and Fig. 2).
Table 1. Demographic and clinical characteristics of the matched patients
Characteristic
Treatment cohort
Ciclesonide n=1,244 Fine-particle ICS n=1,244
Female sex* 808 (65.0) 808 (65.0)
Age in years, median (IQR) 45 (34-53) 45 (35-53)††
Age in years, categorized*
   12-20 106 (8.5) 107 (8.6)
   21-30 129 (10.4) 133 (10.7)
   31-40 228 (18.3) 231 (18.6)
   41-50 355 (28.5) 357 (28.7)
   51-60 426 (34.2) 416 (33.4)
Comorbidities and co-medications 
   Evidence of rhinitis† 539 (43.3) 469 (37.7)**
   Evidence of GERD/GERD prophylaxis‡ 504 (40.5) 420 (33.8)††
   Evidence of oral candidiasis*,§ 2 (0.2) 2 (0.2)
Year of ICS therapy initiation, median (IQR)* 2009 (2007-2010) 2009 (2007-2010)
Prior therapy
   SAMA 41 (3.3) 54 (4.3)
   LABA* 8 (0.6) 8 (0.6)
   LTRA* 3 (0.2) 3 (0.2)
   Theophylline 1 (0.1) 0 (0)
Risk-domain asthma control* 1,127 (90.6) 1,127 (90.6)
Asthma-related hospital admissions 24 (1.9) 6 (0.5)**
Acute oral corticosteroid prescriptions||
   0 1,145 (92.0) 1,132 (91.0)
   1 74 (6.0) 95 (7.6)
   ≥2 25 (2.0) 17 (1.4)
Overall asthma control 1,105 (88.8) 1,105 (88.8)
Baseline SABA daily dose*,¶
   0 µg/day 902 (72.5) 902 (72.5)
   1-100 µg/day 269 (21.6) 269 (21.6)
   101-200 µg/day 50 (4.0) 50 (4.0)
   >200 µg/day 23 (1.8) 23 (1.8)
Severe exacerbations
   0 1,127 (90.6) 1,127 (90.6)
   ≥1 117 (9.4) 117 (9.4)
Data are presented as n (%) unless otherwise stated.
GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; 
SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist.
*Matching variable; †Evidence of rhinitis based on prescription of nasal corticosteroids during the baseline year or outcome analysis period; ‡Evidence of GERD/
GERD prophylaxis based on prescriptions of proton-pump inhibitors during the baseline year or outcome analysis period; §Evidence of oral candidiasis at baseline, 
identified as topical oral antifungal prescription for oral candidiasis; ||Acute oral corticosteroid prescription associated with asthma exacerbation treatment, defined 
as all courses that were definitely not maintenance therapy, AND/OR all courses where dosing instructions suggested exacerbation treatment (e.g. 6, 5, 4, 3, 2, 1 re-
ducing, or 30 mg as directed), AND/OR all courses with no dosing instructions, but unlikely to be maintenance therapy, whereby maintenance therapy was defined 
as no evidence of reducing doses instructions, with a prescribed daily dose of <10 mg of prednisolone OR prescriptions of prednisolone tablets at a strength of 1 mg 
per day, with overall script coverage of more than 25% of days in a year; ¶Calculated as (count of inhalers×doses in pack/365)×µg strength; **P<0.01; ††P≤0.001.
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Secondary endpoints and other outcomes
Patients in the ciclesonide cohort received fewer prescriptions 
of other respiratory drugs and had significantly lower ICS daily 
dose exposure than the fine-particle ICS cohort during the out-
come year (Table 3). The odds of a change in therapy during the 
outcome year were significantly lower for patients prescribed 
ciclesonide than those prescribed fine-particle ICS (adjusted 
odds ratio [95% confidence interval], 0.70 [0.59-0.83]). Similar-
Table 2. Outcome measures during a 1-year period after ICS initiation
Characteristic
Treatment cohort
P value
Ciclesonide n=1,244 Fine-particle ICS n=1,244
No. of severe exacerbations
   0 1,123 (90.3) 1,065 (85.6) <0.001
   1-2 107 (8.6) 163 (13.1)
   3-4 11 (0.9) 11 (0.9)
   ≥5 3 (0.2) 5 (0.4)
Risk-domain asthma control, controlled 1,123 (90.3) 1,065 (85.6) <0.001
Overall asthma control, controlled 1,075 (86.4) 947 (76.1) <0.001
No. of asthma-related hospital admissions
   1 7 (0.6) 7 (0.6) 0.81
   2 2 (0.2) 1 (0.1)
SABA daily dose
   0 µg/day 733 (58.9) 487 (39.1) <0.001
   1-100 µg/day 305 (24.5) 309 (24.8)
   >100 µg/day 206 (16.6) 448 (36.0)
Change in therapy at any time during outcome period* 329 (26.4) 416 (33.4) <0.001
Controller-to-total medication ratio†
   <0.5 34 (2.7) 112 (9.0) <0.001
   0.5-<0.8 311 (25.0) 530 (42.6)
   0.8-<1 166 (13.3) 115 (9.2)
   1 733 (58.9) 487 (39.1)
≥1 prescription of antifungal‡ 29 (2.3) 19 (1.5) 0.14
Data are presented as n (%).
ICS, inhaled corticosteroid; SABA, short-acting β2-agonist.
*Change in therapy during the outcome year was defined as an ICS dose increase of ≥50% or addition of new therapy including a leukotriene receptor antagonist, 
theophylline, or long-acting β2-agonist; †The controller-to-total medication ratio was defined as the number of controller units/(number of controller units+number of 
reliever units), where controllers included ICS and LTRA; ‡Antifungal medication definitely prescribed for treating oral candidiasis.
Fig. 1. Dose of inhaled corticosteroids prescribed at the initiation date. The doses of ciclesonide and fluticasone are reported as actual doses; the beclomethasone 
doses were halved and thus reported as fluticasone-equivalents, as per recommendations regarding corticosteroid equivalence.1-3,6
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Fig. 2. Adjusted rate ratios (RRs) and odds ratios (ORs) for ciclesonide relative to fine-particle ICS during the 1 outcome year for the co-primary endpoints (severe ex-
acerbation RR, risk domain asthma control OR, and overall asthma control OR) and secondary endpoints (change in therapy OR and daily short-acting β2-agonist 
[SABA] use OR). *Adjusted for prescriptions of proton-pump inhibitors (yes/no) and baseline severe exacerbations (categorized); †Adjusted for age and prescriptions 
of proton-pump inhibitors (yes/no); ‡Adjusted for baseline overall asthma control and prescriptions of proton pump inhibitors (yes/no); §Adjusted for prescriptions of 
nasal corticosteroid preparations (yes/no); IIAdjusted for age and baseline SABA daily dose.
Table 3. Respiratory drugs prescribed during the outcome year
Variable
Treatment cohort
P value
Ciclesonide n=1,244 Fine-particle ICS n=1,244
Acute oral corticosteroid courses, n (%)
   0 1,128 (90.7) 1,068 (85.9) <0.001
   1 77 (6.2) 123 (9.9)
   ≥2 39 (3.1) 53 (4.3)
SABA prescriptions, n (%)
   0 733 (58.9) 487 (39.1) <0.001
   1 240 (19.3) 231 (18.6)
   2 137 (11.0) 259 (20.8)
   ≥3 134 (10.8) 267 (21.5)
ICS daily dose exposure, median (IQR)* 126 (78-185) 332 (248-656) <0.001
Average ICS daily dose exposure, n (%)*
   0-150 µg/day 760 (61.1) 382 (30.7) <0.001
   151-250 µg/day 299 (24.0) 478 (38.4)
   251-450 µg/day 143 (11.5) 215 (17.3)
   >450 µg/day 42 (3.4) 169 (13.6)
ICS prescriptions, n (%)
   2 406 (32.6) 576 (46.3) <0.001
   3 275 (22.1) 240 (19.3)
   ≥4 563 (45.3) 428 (34.4)
≥1 LABA prescription, n (%) 559 (44.9) 666 (53.5) <0.001
≥1 LTRA prescription, n (%) 52 (4.2) 38 (3.1) 0.13
ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; SABA, short-acting β2-agonist.
*ICS daily dose exposure calculated as (count of inhalers×doses in pack/365)×µg strength, using actual doses for ciclesonide and fluticasone-equivalent doses for 
fine-particle ICS, as per recommendations for corticosteroid equivalence.1-3,6
0.2 0.5
Adjusted rate/odds ratios (95% CI) for extrafine ICS ciclesonide
Fine-particle ICS=1.00
1 2 3
Severe exacerbations
Risk-domain asthma control
Overall asthma control
Change in therapy
Average SABA daily dose
0.69 (0.53-0.89)*
1.62 (1.27-2.06)†
2.08 (1.68-2.57)‡
0.70 (0.59-0.83)§
0.40 (0.34-0.47)II
Higher with ciclesonide
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ly, the odds of being prescribed a higher SABA dose during the 
outcome period significantly favored the ciclesonide cohort 
(Table 2 and Fig. 2). Subanalysis results for the patients with ev-
idence of rhinitis (prescribed nasal corticosteroids) were simi-
lar to those of the main analysis (Supplementary Table 2).
During the outcome year, patients prescribed ciclesonide re-
ceived a significantly higher ratio of controller-to-total medica-
tion than those prescribed fine-particle ICS (Table 2). Although 
patients in the ciclesonide cohort had higher hospital admissions 
during the baseline year compared with those receiving fine-par-
ticle ICS (1.9% vs 0.5%; P=0.002), this difference was no longer 
observed during the outcome year after ICS initiation (0.7% vs 
0.6% patients prescribed fine-particle ICS; P=0.81; Table 2).
Prescriptions of oral antifungal medications for treating oral 
candidiasis were similar in both treatment cohorts at baseline 
and during the outcome year.
DISCUSSION
In our population-based matched cohort study, we observed 
that patients prescribed extrafine-particle ciclesonide experi-
enced significantly lower rates of severe exacerbations, i.e., hos-
pitalizations or acute oral corticosteroid courses, in the first 
year after initiating ICS treatment than those prescribed fine-
particle ICS, and ciclesonide prescribing was associated with 
better odds of achieving asthma control. Patients prescribed 
ciclesonide were also significantly less likely to require a change 
in therapy or higher doses of reliever medication than those 
prescribed fine-particle ICS. Notably, the prescribed doses of 
ciclesonide were one-third those of fine-particle ICS at the initi-
ation date despite matching for patient characteristics (median 
dose, 160 vs 500 µg/day); and ICS dose exposure during the 
outcome year was also significantly lower for the ciclesonide 
cohort (median, 126 vs 332 µg/day). The drop in the dose of 
both ICS from the initial prescribed dose was likely the result of 
incomplete adherence during the outcome year, a common 
finding in real life.31
We matched the cohorts for important clinical asthma pa-
rameters, including baseline risk-domain asthma control status 
(capturing asthma-related hospitalizations and oral corticoste-
roid bursts during the baseline year), baseline SABA dose, and 
demographic characteristics (sex and age). Nevertheless, the 
ciclesonide cohort presented with signs of more difficult-to-
control asthma at baseline in the form of greater frequency of 
nasal corticosteroid and proton pump inhibitor prescrip-
tions.1,32 This would presumably favor better asthma control in 
the outcome year for the fine-particle ICS cohort. Moreover, de-
spite higher baseline hospital admissions in the ciclesonide 
than in the fine-particle ICS cohort, there was no difference in 
outcome hospitalizations. These findings suggest a clinically 
significant improvement in asthma control for patients pre-
scribed ciclesonide who had unstable disease and thus would 
classically be excluded from randomized controlled trials.
Possible mechanisms to explain better effectiveness of cicle-
sonide include (1) improved airway drug distribution, includ-
ing small airways4,7,8,10; (2) decreased impact of errors in inhala-
tion techniques (especially poor coordination or too fast inha-
lation flow rate) on lung deposition33,34; and (3) improved ad-
herence, promoted by greater perception of treatment effects, 
once daily dosing, or reassurance as to the dose of corticoste-
roid. Moreover, compared to those prescribed fine-particle ICS, 
more patients prescribed ciclesonide had a controller-to-total 
medication ratio of ≥0.5, a finding associated with improved 
asthma-related quality of life, better disease control, and re-
duced symptoms.35
There are several limitations to this study. Exclusion of pa-
tients without data during a 1-year period before and 1 year af-
ter ICS initiation meant that patients who moved or died were 
not represented. The requirement that all patients have 1-year 
outcome data predisposed the study to survivor bias. However, 
this may not have had a major effect, given the median age of 
45 years and because patients prescribed their first ICS are un-
likely to have severe asthma. Other limitations are those com-
mon to observational studies: biases deriving from unmea-
sured confounders that may particularly affect 1 of the 2 treat-
ment strategies, non-random assignment of drug treatment, 
and potential misclassification bias and under-reporting if 
medical attention was not sought.
During the study period, ciclesonide was not the most com-
mon ICS prescribed in the Netherlands, although it was pre-
scribed for 34% of patients. Thus, there may be unrecorded rea-
sons physicians chose to prescribe ciclesonide, resulting in pre-
scription bias. This channeling phenomenon was suggested 
given that patients prescribed ciclesonide had signs of difficult-
to-treat asthma (rhinitis and gastroesophageal reflux),32 find-
ings potentially reducing positive effects of ciclesonide versus 
fine-particle ICS on asthma outcomes, which was not the case. 
While 1,244/1,382 (90%) eligible patients initiating ciclesonide 
were matched, only 1,244/2,682 (46%) of those initiating fine-
particle ICS were matched, suggesting the possibility that pa-
tients in the fine-particle cohort were not representative of 
those who initiate fine-particle ICS therapy in the Netherlands.
Finally, our analyses were limited by data availability; for ex-
ample, smoking history, which may have some impact on ef-
fectiveness of ICS,17,36 was not available, and nor were body 
mass index and lung function data. Diagnostic information was 
inferred from prescribing data. This meant that patients were 
selected as having asthma based on prescribed therapy, poten-
tially leading to diagnostic misclassification. To mitigate this, 
we excluded patients with only 1 ICS prescription, which could 
have been a therapy trial. We were not able to assess current 
clinical control, but SABA dose (based on prescriptions) served 
as an indication of symptom control: 83% and 64% of patients 
in the ciclesonide and fine-particle ICS cohorts, respectively, 
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were prescribed ≤1 puff/day (≤100 µg/day) of SABA on aver-
age, well within the definition of good control of asthma from 
an administrative database.37 The actual use of SABA was likely 
lower, as patients tend to have multiple inhalers and do not use 
all of the prescribed canisters.
This study also has several strengths. Patients were drawn 
from a large diverse population with subsequent 1:1 exact 
matching on key baseline characteristics to ensure that the 2 
cohorts were as comparable as possible with respect to demo-
graphic and clinical characteristics.30 Outcome measures were 
adjusted for appropriate non-collinear baseline confounders.
The 1-year baseline and outcome periods enabled us to identi-
fy measurable changes in endpoints, such as hospitalizations, 
severe exacerbations, and asthma control, and also to allow for 
seasonal changes in respiratory conditions. All patients were 
prescribed the same inhaler type for ICS (pMDI), minimizing 
outcome differences associated with inhalation techniques for 
ICS or mixing inhaler devices (most SABA inhalers prescribed 
in the Netherlands are pMDIs).6,38
The residual baseline differences between treatment cohorts 
after matching (i.e., greater frequency of rhinitis and gastro-
esophageal reflux prescriptions in the ciclesonide treatment co-
hort) were addressed in the statistical models. Nasal corticoste-
roid prescriptions were not significant in the statistical model 
for the co-primary endpoints, suggesting that these did not af-
fect the results, and the subgroup analysis of patients receiving 
nasal corticosteroid prescriptions corroborated the main find-
ings. The co-primary endpoints were all adjusted for proton 
pump inhibitor prescriptions.
Guidelines recommend that fluticasone and ciclesonide be 
prescribed at similar nominal doses1-3,6,15 based on equipotence 
in formal testing in randomized trials. Despite these recom-
mendations, we found that in practice, ciclesonide was pre-
scribed at lower doses than fluticasone and that fluticasone was 
typically prescribed at higher than recommended doses, cor-
roborating findings from prior studies in the Netherlands, as 
well as New Zealand, the UK, and the USA.21,22,39,40 Lower doses 
of ICS may be associated with reduced adverse events;41,42 fur-
ther research is required to determine whether the lower pre-
scribed doses of ciclesonide and of extrafine-particle beclo-
methasone in prior studies21,22 are associated with fewer adverse 
events in real-life populations, an important consideration for 
long-term asthma controller therapies and one that requires 
further studies, as we could not capture drug-related adverse 
events from our data source. Extrafine-particle ICS have rela-
tively low oropharyngeal deposition, which could potentially 
lead to fewer oral side effects than with larger particle ICS.8,15,18,43 
However, we found that the proportion of patients prescribed 
antifungal medication for oral candidiasis was low and similar 
in the ciclesonide and fine-particle ICS treatment cohorts (2.3% 
vs 1.5%).
In conclusion, the results of this matched cohort analysis sug-
gest that initiation of ICS with ciclesonide is associated with 
better 1-year asthma outcomes and fewer changes to therapy 
in that year, at one-third of the prescribed dose than with fine-
particle ICS. The study drew on reliable dispensing and hospi-
talization data for a real-life Dutch population—presumably in-
cluding smokers and non-smokers, patients with good and bad 
inhaler techniques, stable and unstable asthma, and good and 
bad adherence. The association of better outcomes with cicle-
sonide therapy was present, even though asthma was some-
what more severe in those prescribed ciclesonide. More real-
life observational or randomized controlled studies of other pa-
tient populations and different extrafine-particle ICS are need-
ed to further explore these findings.
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